Australia's ALS gains as brokerages remain upbeat after half-year results

ALS

19/11/2025 24:43

Updates

** Shares of ALS Ltd ALQ.AX rise as much as 2.9% to A$21.47, their largest intraday pct gain since October 6

** Citi upgrades target price for laboratory testing services provider to A$23.8 from A$19.45, maintains "buy" tag

** ALS on Tuesday reported a 17.2% jump in underlying NPAT to A$178.4 million for HY

** Citi says co's commodities segment surprised on the upside with sample volumes up "low double-digit" compared to last year

** Says co's revised forecast of 12% to 14% organic revenue growth for commodities division appears conservative; brokerage estimates 15% growth

** Macquarie hikes EPS estimates for ALS by 6% to 7% for fiscals 2027, 2028 and 2029 each

** Says stock has had a "strong run and multiple", but should be supported by co's strong earnings growth profile which is above market and global peers

** Brokerage retains "outperform" rating, target price A$22.85

** Stock up 39.1% YTD, including the day's moves

(Reporting by Nikita Maria Jino in Bengaluru)

((Nikita.Jino@thomsonreuters.com;))